The Neuro-Inflammation Link: Is Your Brain “On Fire”?

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Within the Adelaide functional medicine community, there is growing recognition that the traditional “chemical imbalance” model of depression is incomplete. A growing body of research suggests that, in a subset of individuals, depressive symptoms are associated with immune activation and chronic, low-grade inflammation. Neuroinflammation depression in Adelaide is linked to the kynurenine pathway, which plays a crucial role in mood regulation, inflammation, and mental health disorders like depression. At Elemental Health and Nutrition, mood concerns are explored through an inflammatory and metabolic lens, particularly when standard approaches have provided limited relief. This perspective aligns with broader work in neuro-inflammation and mood disorders.

Quick Answer: How Can Inflammation Influence Depression?

Inflammation may influence mood by activating the brain’s resident immune cells, known as microglia, and initiating a pattern known as “sickness behaviour” (2,4). Pro-inflammatory signalling can up-regulate the kynurenine pathway, diverting tryptophan away from serotonin synthesis and toward metabolites such as quinolinic acid (1,5). This biochemical shift has been associated with symptoms including low mood, fatigue, cognitive slowing, and reduced motivation (8,15,21).

The Science: The Kynurenine “Shunt”

When the body is exposed to ongoing physiological or psychological stress—such as infection, gut dysbiosis, or prolonged psychosocial stress—immune signalling may take precedence over neurotransmitter balance.

• IDO Enzyme Activation: Pro-inflammatory cytokines, including IL-6 and TNF-α, can activate the enzyme indoleamine 2,3-dioxygenase (IDO), increasing the conversion of tryptophan into kynurenine (1,5).
• Tryptophan Diversion: Under inflammatory conditions, supplemental tryptophan or 5-HTP may be preferentially metabolised along the kynurenine pathway rather than toward serotonin synthesis (12,17).
• Excitotoxic Stress: Elevated quinolinic acid is an NMDA-receptor agonist and has been linked to excitotoxic stress and structural vulnerability in mood-regulating brain regions such as the hippocampus (18,20).

Sickness Behaviour vs. Persistent Low Mood

“Sickness behaviour” is an adaptive, evolutionarily conserved response that promotes rest and energy conservation during acute illness (2,9). Difficulties arise when inflammatory signalling becomes chronic rather than time-limited.

• Anhedonia: Inflammatory mediators have been shown to interfere with dopaminergic reward pathways, contributing to reduced pleasure and motivation (16,19).
• Neuro-Fatigue: Inflammation can impair mitochondrial energy metabolism, which may contribute to cognitive fatigue and mental exhaustion. This pattern commonly overlaps with presentations seen in chronic fatigue and post-viral syndromes (15,22).

Advanced Inflammatory Mapping in Adelaide

In clinical practice, potential inflammatory contributors to mood symptoms are explored using objective biomarkers rather than symptoms alone:

• hs-CRP (High-Sensitivity C-Reactive Protein): A marker of systemic inflammation. Levels above approximately 1.0 mg/L have been associated with an increased risk of depressive symptoms in population studies (2,11).
• Homocysteine: Elevated levels may reflect impaired methylation capacity and have been linked to neuro-inflammatory processes (12,15).
• Organic Acids Testing (OAT): Measurement of kynurenic and quinolinic acid can help determine whether tryptophan metabolism is favouring the kynurenine pathway. This is commonly assessed using Organic Acids Testing (OAT) in functional medicine practice (1,21).

Botanical and Nutritional Anti-Inflammatory Support

When inflammation appears to be a contributing factor, evidence-informed nutritional and botanical strategies may be considered as part of a broader, individualised care plan:

• Curcumin (Phytosome formulations): Curcumin has demonstrated central nervous system activity and has been shown to influence inflammatory signalling pathways, including those involved in IDO activation (10,20).
• Omega-3 Fatty Acids (EPA/DHA): Higher EPA intake has been associated with reduced inflammatory signalling and modulation of microglial activity in both clinical and experimental research (13,19).
• Saffron (Crocus sativus): Clinical trials suggest saffron may improve symptoms in mild-to-moderate depression, with proposed mechanisms including antioxidant and anti-inflammatory effects (17,21).

Key Insights

• Depressive symptoms are frequently associated with chronic, low-grade inflammation (2,4).
• The kynurenine pathway provides a biological framework linking inflammation and serotonin depletion (1,5).
• Neuro-inflammation has been linked to structural and functional changes in mood-regulating brain regions (18,20).
• Biomarkers such as hs-CRP and kynurenine metabolites can help clarify inflammatory contributions to mood symptoms (2,21).

Next Steps

If low mood persists despite conventional approaches, inflammatory or metabolic contributors may warrant further exploration. A structured assessment can help determine whether neuro-inflammatory pathways are relevant in an individual context.

References

1. Schwarcz R et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012 Jul 18;13(8):546-58. https://doi.org/10.1038/nrn3257
2. Miller AH et al. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016 Jan;16(1):22-34. https://doi.org/10.1038/nri.2015.5
3. Khandaker GM et al. Association of serum interleukin 6 and C-reactive protein with depression: a systematic review and meta-analysis. JAMA Psychiatry. 2014 Oct;71(10):1121-8. https://doi.org/10.1001/jamapsychiatry.2014.1333
4. Setiawan E et al. Role of neuroinflammation in major depressive disorder: a voxel-based meta-analysis of neuroimaging studies. JAMA Psychiatry. 2015 Aug;72(8):803-11. https://doi.org/10.1001/jamapsychiatry.2015.0764
5. Dantzer R et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008 Jan;9(1):46-56. https://doi.org/10.1038/nrn2297
6. Köhler O et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014 Dec;71(12):1381-91. https://doi.org/10.1001/jamapsychiatry.2014.1611
7. Felger JC et al. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013 Aug 29;246:199-229. https://doi.org/10.1016/j.neuroscience.2013.04.060
8. Slavich GM et al. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014 May;140(3):774-815. https://doi.org/10.1037/a0035302
9. Kelley KW et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003 Feb;17 Suppl 1:S112-8. https://doi.org/10.1016/s0889-1591(02)00072-3
10. Lopresti AL et al. Curcumin for major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2014 Oct;167:368-75. https://doi.org/10.1016/j.jad.2014.06.001
11. Raison CL et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013 Jan;70(1):31-41. https://doi.org/10.1001/2013.jamapsychiatry.4
12. Myint AM et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007 Apr;98(3):143-51. https://doi.org/10.1016/j.jad.2006.07.013
13. Kiecolt-Glaser JK et al. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun. 2011 Nov;25(8):1725-34. https://doi.org/10.1016/j.bbi.2011.07.229
14. Dash S et al. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry. 2015 Jan;28(1):1-6. https://doi.org/10.1097/YCO.0000000000000117
15. Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014 May;16:7-17. https://doi.org/10.1016/j.mito.2013.08.006
16. Capuron L et al. Dopaminergic mechanisms of reduced basal ganglia responses to food rewards in depression. Mol Psychiatry. 2012 Mar;17(3):327-36. https://doi.org/10.1038/mp.2010.147
17. Hausenblas HA et al. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013 Nov;11(6):377-83. https://doi.org/10.3736/jintegrmed2013056
18. Haroon E et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry. 2016 Oct;21(10):1351-7. https://doi.org/10.1038/mp.2015.206
19. Pariante CM. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559. https://doi.org/10.1016/j.euroneuro.2017.02.006
20. Ng QX et al. Clinical use of curcumin in depression: a meta-analysis of randomized controlled trials. J Am Med Dir Assoc. 2017 Jul 1;18(7):628-633. https://doi.org/10.1016/j.jamda.2017.03.009
21. O’Mahony SM et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015 Feb 15;277:32-48. https://doi.org/10.1016/j.bbr.2014.07.027
22. Lord RS, Bralley JA. Laboratory evaluations for integrative and functional medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008.